Latest Breaking News On - Overall survival - Page 15 : comparemela.com

TME Pharma Announces Final Median Overall Survival Data Reaching 19 9 Months for NOX-A12 Combination Regimen in GLORIA Brain Cancer Trial and Survival Rate 10-Fold Greater Than Standard of Care

TME Pharma Announces Final Median Overall Survival Data Reaching 19 9 Months for NOX-A12 Combination Regimen in GLORIA Brain Cancer Trial and Survival Rate 10-Fold Greater Than Standard of Care
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesPharmanv euronextMerck keytrudaGuillaume van renterghemArthur rouillAram mangasarianMerck sharp dohme corpDrug administrationNew drugFast track designationEuronext growth parisInvestigational new drugMerck sharpOverall survivalMedia relations

TME Pharma N V : TME Pharma Announces Final Median Overall Survival Data Reaching 19 9 Months for NOX-A12 Combination Regimen in GLORIA Brain Cancer Trial and Survival Rate 10-Fold Greater Than Standard of Care

TME Pharma N V : TME Pharma Announces Final Median Overall Survival Data Reaching 19 9 Months for NOX-A12 Combination Regimen in GLORIA Brain Cancer Trial and Survival Rate 10-Fold Greater Than Standard of Care
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

France generalUnited statesMerck keytrudaPharmanv euronextArthur rouillStefan klotterAram mangasarianGuillaume van renterghemMerck sharp dohme corpDrug administrationNew drugFast track designationEuronext growth parisInvestigational new drugMerck sharp dohmeOverall survival

Immutep Quarterly Activities Report Q2 FY24

Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer patients expressing PD-L1.

New south walesSouth australiaChris bastaFrederic triebelJamie rossjohnCorporate communicationsKorean intellectual property officeMerck kgaCommittee for medicinal products human useData monitoring committeeMonash universityImmutep limitedGlobenewswire incMerck kgaaOverall survivalOverall response rate

RenovoRx Closes $6 1 Million Private Placement

LOS ALTOS, Calif. (BUSINESS WIRE) Jan 29, 2024

United statesRobertj spiegelJack perkinsMarta wypychShaun bagaiData monitoring committeeSecurities exchangePaulson investment companyRenovorx incAmerican association for cancer research annual meetingCompany nasdaqExchange commissionCompany phaseStrategic communicationsR pac phaseNasdaq stock market

As patients live longer, new criteria needed for prostate cancer trials

As patients live longer, new criteria needed for prostate cancer trials
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United statesSusan halabiMaha hussainDivision of hematologyRoberth lurie comprehensive cancer centerNorthwestern universityCenters for diseaseClinical oncologyDisease controlComprehensive cancer centerRadiographic progression free survivalClinical progression free survivalPotential surrogatesOverall survival